Article Details
Retrieved on: 2024-04-23 16:03:18
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Repligen operates in attractive end markets, historically targeting monoclonal antibodies (10% to 12% market growth) and moving into cell and gene ...
Article found on: www.insidermonkey.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here